Aptus Capital Advisors, LLC Brainstorm Cell Therapeutics Inc. Transaction History

Aptus Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	BUY	$2.55 - $4.42 $382 - $663	150 Added 1.47%	10,360 $46,000
Q2 2022 Jul 29, 2022	SELL	$2.71 - $3.6 $6,205 - $8,244	-2,290 Reduced 18.32%	10,210 $28,000
Q4 2021 Feb 02, 2022	SELL	$2.81 - $4.23 $9,835 - $14,805	-3,500 Reduced 21.88%	12,500 $50,000
Q3 2021 Oct 27, 2021	SELL	$3.14 - $4.09 $7,379 - $9,611	-2,350 Reduced 12.81%	16,000 $53,000
Q2 2021 Jul 27, 2021	BUY	$3.01 - $4.01 $6,922 - $9,223	2,300 Added 14.33%	18,350 $70,000
Q1 2021 May 06, 2021	SELL	$3.46 - $7.88 $62,626 - $142,628	-18,100 Reduced 53.0%	16,050 $61,000
Q4 2020 Feb 10, 2021	BUY	$3.99 - $17.73 $136,258 - $605,479	34,150 New	34,150 $154,000

10.5M

160K

30.5K

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $69.3M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

Get notified when there are updates to the investment portfolio of Aptus Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Aptus Capital Advisors, LLC with notifications on news.